Anbio Biotechnology (NNNN) names GGF CPA LTD as new independent auditor

Rhea-AI Filing Summary

Anbio Biotechnology reported a change in its independent registered public accounting firm. On February 11, 2026, the Board of Directors and Audit Committee approved and ratified the appointment of GGF CPA LTD to audit the company’s financial statements, effective the same date. The report states that during the two most recent fiscal years ended December 31, 2025 and 2024, and subsequent interim periods before this engagement, neither the company nor anyone on its behalf consulted GGF CPA LTD. A letter from the former auditor, HTL International, LLC, addressed to the U.S. Securities and Exchange Commission is included as Exhibit 16.1.

Insights

Audit & Governance Analyst

Anbio replaces its external auditor, appointing GGF CPA LTD from February 11, 2026.

Anbio Biotechnology has changed its independent registered public accounting firm, with the Board and Audit Committee jointly approving GGF CPA LTD to audit financial statements effective February 11, 2026. Such approvals indicate the decision followed the company’s formal governance process.

The disclosure notes that during fiscal years ended December 31, 2025 and 2024, and interim periods before engagement, neither the company nor representatives consulted GGF CPA LTD. This clarifies that there was no prior advisory relationship with the new firm during those periods.

The filing also references a letter from former auditor HTL International, LLC to the SEC as Exhibit 16.1. Future periodic reports will reflect GGF CPA LTD’s role in auditing Anbio’s financial statements, and investors can review those reports to see the new auditor’s signed opinions.

FAQ

What did Anbio Biotechnology (NNNN) announce in its February 2026 6-K?

Anbio Biotechnology announced a change in its independent registered public accounting firm. The Board and Audit Committee approved and ratified the appointment of GGF CPA LTD to audit the company’s financial statements, effective February 11, 2026, replacing the prior audit firm.

Who is the new independent auditor for Anbio Biotechnology (NNNN)?

The new independent registered public accounting firm for Anbio Biotechnology is GGF CPA LTD. The Board of Directors and Audit Committee approved and ratified this appointment on February 11, 2026, with the firm engaged to audit the company’s financial statements going forward.

Did Anbio Biotechnology consult GGF CPA LTD before appointing them as auditor?

The company states that during the two most recent fiscal years ended December 31, 2025 and 2024, and subsequent interim periods before engagement, neither Anbio Biotechnology nor anyone on its behalf consulted GGF CPA LTD regarding auditing matters or other issues covered in the disclosure.

Which prior auditor of Anbio Biotechnology (NNNN) sent a letter to the SEC?

The prior auditor, HTL International, LLC, provided a letter addressed to the U.S. Securities and Exchange Commission. This letter is identified as Exhibit 16.1 and accompanies Anbio Biotechnology’s 6-K reporting the change in the company’s independent registered public accounting firm.

What role did Anbio Biotechnology’s Audit Committee play in the auditor change?

Anbio Biotechnology’s Audit Committee, together with the Board of Directors, approved and ratified the appointment of GGF CPA LTD as the new independent registered public accounting firm on February 11, 2026, reflecting that the change followed the company’s established governance procedures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-42526

Anbio Biotechnology

Friedrich-Ebert-Anlage 35-37, 60327
Frankfurt am Main,
Germany
+49 69870039170

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Changes in Company’s Certifying Accountant.

(1) Previous Independent Registered Public Accounting Firm

(i) Effective on February 11, 2026, the Board of Directors (the “Board”) and the Audit Committee of Anbio Biotechnology (the “Company”) approved the dismissal of HTL International, LLC as the Company’s independent registered public accounting firm.

(ii) Following discussions between the Company and HTL International, LLC, the Audit Committee determined that engaging a new auditor with sufficient available capacity to meet the Company’s reporting timeline and ensure the timely completion of the audit of the Company’s financial statements and the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, would be in the best interests of the Company. HTL International, LLC was appointed as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025 on November 10, 2025 and did not be asked to issue an audit report on the Company’s financial statements for the fiscal year ended December 31, 2025. During the period of HTL International, LLC’s engagement and through February 11, 2026, there were no disagreements between the Company and HTL International, LLC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of HTL International, LLC, would have caused HTL International, LLC to make reference to the subject matter of the disagreements in connection with its reports.

(iii) The Company provided HTL International, LLC with a copy of this Current Report and has requested that it furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter is attached as Exhibit 16.1 to this Report of Foreign Private Issuer on Form 6-K.

(2) New Independent Registered Public Accounting Firm

On February 11, 2026, the Board of Directors of the Company and the Audit Committee of the Company approved and ratified the appointment of GGF CPA LTD as its new independent registered public accounting firm to audit the Company’s financial statements, effective February 11, 2026. During the two most recent fiscal years ended December 31, 2025 and 2024 and any subsequent interim periods through the date hereof prior to the engagement of GGF CPA LTD, neither the Company, nor someone on its behalf, has consulted GGF CPA LTD regarding:

(i) either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and either a written report was provided to the Company or oral advice was provided that the new independent registered public accounting firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or

(ii) any matter that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable event as described in paragraph 304(a)(1)(v) of Regulation S-K.

Exhibit Index

Exhibit No.		Description
16.1		Letter from HTL International, LLC addressed to the U.S. Securities and Exchange Commission

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Anbio Biotechnology
Date: February 17, 2026	By:	/s/ Michael Lau
	Name:	Michael Lau
	Title:	Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-16.1 EXHIBIT 16.1 3.0 KB
• EX-16 GRAPHIC 11.8 KB
• EX-16 GRAPHIC 19.2 KB